ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,934.40
-0.61%
US Tech 100
20,739.20
-0.78%
다우존스 지수
42,739.06
-0.59%
Bitcoin
94,544.25
1.10%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Genenta Science SPA (GNTA)

  7. Genenta Science SPA (GNTA) 뉴스

Genenta Science SPA

Genenta Science SPA (GNTA)

NASDAQ
5.448
0.568
( 11.64% )
업데이트: 03:05:26
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

GNTA 뉴스

공식 뉴스 전용

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
21 12월 2024
GNTA (11.64%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
21 12월 2024
GNTA (11.64%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
14 12월 2024
GNTA (11.64%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
15 11월 2024
GNTA (11.64%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
30 10월 2024
GNTA (11.64%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
21 10월 2023
GNTA (11.64%)

GNTA Discussion

게시물 보기
Monksdream Monksdream 1 주 전
GNTA under $6
👍️0
Monksdream Monksdream 1 주 전
GNTA under $5
👍️0
Monksdream Monksdream 2 월 전
GNTA under $6
👍️0
Awl416 Awl416 5 월 전
What leaked
👍️0
Monksdream Monksdream 8 월 전
GNTA under $3
👍️0
Luckypennyman Luckypennyman 2 년 전
FDA’s decision to grant Orphan Drug Designation to Temferon









glta
👍️0
makinezmoney makinezmoney 2 년 전
$GNTA: Just got a $15 PriceTarget upgrade.

From here $5, looks like its gonna be a nice ride up


GO $GNTA
👍️0
conix conix 3 년 전
Maxim starts Genenta Science at buy; PT $21

Stephen Kilmer

January 13, 2022

Maxim Group launched coverage of Genenta Science S.p.A (NASDAQ:GNTA) with a “buy” rating and $21 price target. The stock closed at $9.94 on Jan. 12.

Genenta is developing cancer therapeutics using an autologous ex-vivo, lentiviral-based gene therapy strategy.

The company initially is targeting unmethylated-MGMT glioblastoma multiforme (GBM) patients with its lead gene therapy, Temferon, which is currently being evaluated in a Phase 1/2 dose-escalation study. Data from the latter two cohorts are expected around the end of 2022.

“Tumor agnostic gene therapy, Temferon, can potentially be applied broadly to multiple cancer types because it is not tumor dependent,” writes analyst Naureen Quibria, Ph.D.

She said lentiviral-based gene therapy is a validated approach, with treatment approvals seen in Kymriah for acute lymphoblastic leukemia and diffuse large B-cell lymphoma, Zynteglo for ß-thalassemia, and Libmeldy for metachromatic leukodystrophy.

Genenta’s Temferon, has also demonstrated initial signals of efficacy in its Phase 1/2 clinical study in GBM, as well as robust activity in multiple tumor models in preclinical studies.

“Though the program is somewhat early, we believe the broad utility of the platform and potential durability of the approach support a ‘buy’ rating and our $21 price target,” Dr. Quibria said.
👍️0
asser_al7ob asser_al7ob 3 년 전
is this genta that we have before, it is coming back after years
👍️0
Phosphene Phosphene 3 년 전
Clinical-stage biotechnology company pioneering
the development of lentivirus-based first-in-class
gene and cell therapies in cancer.

Genenta uses gene-based cytokine delivery
to activate the immune system within the tumor,
providing a controlled, targeted and enduring anti-tumor response.

https://www.genenta.com/

TEM-GBM_001

👍️0

최근 히스토리

NASDAQ
GNTA
Genenta Science
BIT
F16972
Vontobel Financial Produ...
BIT
F29099
Vontobel Financial Produ...
BIT
BUND5L
Solactive leveraged long...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유